Groud breaking research funded by 920,000 EUR grant from French ANR
Paris, March 18, 2009 — Magnisense, a developer of next generation bioassays for human and animal diagnostics, food safety and environmental protection, announces today the launch of a new discovery platform for the construction and characterization of next generation nanomagnetic materials. This work, in collaboration with the Paris 13 University and the Claude Bernard Lyon 1 University, is funded by a 920,000 EUR grant from l’Agence Nationale de la Recherche (ANR). It also benefits the subsidies of the French agency for innovation, OSEO.
Thanks to its innovative MIAplex® technology, Magnisense is a pioneer in the development of multiparametric magnetic point of care tests. MIAplex® permits the direct detection and quantification of multiple biologic targets in the same sample volume by utilizing the unique magnetic signature of differing magnetic beads.
The joint discovery platform identifies and develops new families of magnetic beads for Magnisense MIAplex® detection. The new magnetic beads are characterized by their characteristic magnetic signatures. These unique beads are a key element of the development of the MIAplex® multiparametric diagnostic technology. In addition, the discovery of these unique beads is expected to further increase the sensitivity of MIAtek® monoparametric detection. Lastly, the discovery of these unique beads makes quantitative in vivo monitoring a likely possibility.
The group Bionanomatériaux directed by Pr. Laurence Motte, team C2B, laboratory CSPBAT, Paris 13 University, experiments with inorganic nanometric materials (metallic oxides) for biomedical applications: nanobiomarkers for in vitro multiparametric investigation, or nanovectors for MRI and/or therapeutics. This work is pursued in concert with the Bioorganic Chemistry group.
«The support of the ANR validates the scientific ambitions of this University-Industry collaboration with Magnisense. For our team, this grant is a vindication of the quality of our work. » signed Pr. Laurence Motte.
«Our collaboration with the universities Paris 13 and Claude Bernard Lyon 1 aims to build in France a unique platform in the world of discovery, development and characterization of nanomagnetic materials for in vitro diagnostics» comments Luc Lenglet, C.E.O. of Magnisense. «We would like to thank the ANR and OSEO who have made the successful outcome of this ambitious collaboration possible».
About Magnisense:
Magnisense develops and markets magnetic bioassays. These next-generation assays improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing. They are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods.
Magnisense technology provides true quantification of one or more biological targets, even in large volume samples. The magnetic signal is free of interference from environmental factors, permitting a more sensitive and reproducible detection than possible with traditional markers (eg enzymatic or fluorescent).
Magnisense is developing two rapid test formats with a single dose, producing objective, quantifiable and traceable results via a portable reader, for different application areas:
For further information: www.magnisense.com
Press and Analysts Contact: Magnisense |